Corton Capital’s Alto Neuroscience ANRO Stock Holding History

Corton Capital’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-33,553	Closed	-$142K	–	439
2024 Q4	$142K	Buy	+33,553	New	+$209K	0.08%	310

Other funds holding ANRO

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Corton Capital's ANRO Position: Q1 2025 in Review

Corton Capital sold out of Alto Neuroscience (ANRO) in Q1 2025, closing a stake of 33,553 shares — an estimated $142K sold.

Corton Capital first reported a position in ANRO in Q4 2024 and held it in 1 quarter. The position peaked at $142K in Q4 2024. 83 funds tracked by Wall St. Rank hold ANRO as of Q1 2025.

Corton Capital reported no remaining Alto Neuroscience position as of Q1 2025 after selling out during the quarter.
Corton Capital sold 33,553 Alto Neuroscience shares in Q1 2025, an estimated $142K.
Corton Capital first reported a position in Alto Neuroscience in Q4 2024 and held it in 1 quarter.
Corton Capital's Alto Neuroscience position peaked at $142K in Q4 2024.
83 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2025.

Based on Corton Capital's 13F filing for Q1 2025, filed 7 May 2025.